Karuna Therapeutics (KRTX) Stock Forecast, Price Target & Predictions
KRTX Stock Forecast
Karuna Therapeutics stock forecast is as follows: an average price target of $257.50 (represents a -21.93% downside from KRTX’s last price of $329.83) and a rating consensus of 'Buy', based on 6 wall street analysts offering a 1-year stock forecast.
KRTX Price Target
The average price target for Karuna Therapeutics (KRTX) is $257.50 based on 1-year price targets from 6 Wall Street analysts in the past 3 months, with a price target range of $330.00 to $150.00. This represents a potential -21.93% downside from KRTX's last price of $329.83.
KRTX Analyst Ratings
According to 6 Wall Street analysts, Karuna Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for KRTX stock is 0 'Strong Buy' (0.00%), 5 'Buy' (83.33%), 1 'Hold' (16.67%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Karuna Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Dec 26, 2023 | Raghuram Selvaraju | H.C. Wainwright | $330.00 | $317.00 | 4.10% | 0.05% |
| Jan 05, 2023 | - | Piper Sandler | $285.00 | $198.46 | 43.61% | -13.59% |
| Aug 12, 2022 | Yatin Suneja | Guggenheim | $330.00 | $261.31 | 26.29% | 0.05% |
| Aug 08, 2022 | Paul Matteis | Stifel Nicolaus | $260.00 | $241.19 | 7.80% | -21.17% |
| Apr 27, 2022 | - | Mizuho Securities | $190.00 | $120.50 | 57.68% | -42.39% |
| Aug 05, 2021 | Jason McCarthy | Maxim Group | $150.00 | $117.81 | 27.32% | -54.52% |
The latest Karuna Therapeutics stock forecast, released on Dec 26, 2023 by Raghuram Selvaraju from H.C. Wainwright, set a price target of $330.00, which represents a 4.10% increase from the stock price at the time of the forecast ($317.00), and a 0.05% increase from KRTX last price ($329.83).
Karuna Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 1 |
| Avg Price Target | - | - | $330.00 |
| Last Closing Price | $329.83 | $329.83 | $329.83 |
| Upside/Downside | -100.00% | -100.00% | 0.05% |
In the current month, the average price target of Karuna Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Karuna Therapeutics's last price of $329.83. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Dec 28, 2023 | Canaccord Genuity | Buy | Buy | Hold |
| Dec 26, 2023 | H.C. Wainwright | - | Neutral | Downgrade |
| Mar 02, 2023 | Wells Fargo | Overweight | Overweight | Hold |
| Jan 05, 2023 | Piper Sandler | - | Overweight | Initialise |
| Aug 08, 2022 | Wedbush | Outperform | Outperform | Hold |
| Jul 14, 2022 | SVB Leerink | - | Outperform | Initialise |
Karuna Therapeutics's last stock rating was published by Canaccord Genuity on Dec 28, 2023. The company gave KRTX a "Buy" rating, the same as its previous rate.
Karuna Therapeutics Financial Forecast
Karuna Therapeutics Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Dec 22 | Sep 22 | Dec 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | $5.28M | $81.00K | $36.96M |
| Avg Forecast | $56.95M | $44.30M | $32.42M | $20.53M | $53.04M | $3.02M | $562.50K | $3.31M | $862.42K | $1.26M | $416.88K | $7.14K | $916.67K | $7.78M |
| High Forecast | $56.95M | $44.30M | $32.42M | $20.53M | $53.04M | $3.02M | $562.50K | $3.31M | $1.28M | $1.26M | $416.88K | $7.14K | $916.67K | $7.78M |
| Low Forecast | $56.95M | $44.30M | $32.42M | $20.53M | $53.04M | $3.02M | $562.50K | $3.31M | $441.51K | $1.26M | $416.88K | $7.14K | $916.67K | $7.78M |
| # Analysts | - | - | - | - | 2 | 2 | 2 | 3 | 2 | 16 | 8 | 13 | 7 | 6 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 738.91% | 0.09% | 4.75% |
Karuna Therapeutics's average Quarter revenue forecast for Jun 23 based on 8 analysts is $416.88K, with a low forecast of $416.88K, and a high forecast of $416.88K. KRTX's average Quarter revenue forecast represents a -92.10% decrease compared to the company's last Quarter revenue of $5.28M (Dec 22).
Karuna Therapeutics EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Dec 22 | Sep 22 | Dec 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 2 | 2 | 2 | 3 | 2 | 16 | 8 | 13 | 7 | 6 |
| EBITDA | - | - | - | - | - | - | - | - | - | $-136.22M | $-119.91M | $-85.04M | $-80.70M | $-27.72M |
| Avg Forecast | $-11.39M | $-8.86M | $-6.48M | $-4.11M | $-10.61M | $-604.37K | $-112.50K | $-662.50K | $-172.48K | $-251.04K | $-83.38K | $-1.43K | $-183.33K | $-36.34M |
| High Forecast | $-11.39M | $-8.86M | $-6.48M | $-4.11M | $-10.61M | $-604.37K | $-112.50K | $-662.50K | $-88.30K | $-251.04K | $-83.38K | $-1.43K | $-183.33K | $-29.07M |
| Low Forecast | $-11.39M | $-8.86M | $-6.48M | $-4.11M | $-10.61M | $-604.37K | $-112.50K | $-662.50K | $-256.08K | $-251.04K | $-83.38K | $-1.43K | $-183.33K | $-43.61M |
| Surprise % | - | - | - | - | - | - | - | - | - | 542.61% | 1438.15% | 59549.02% | 440.20% | 0.76% |
undefined analysts predict KRTX's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Karuna Therapeutics's previous annual EBITDA (undefined) of $NaN.
Karuna Therapeutics Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Dec 22 | Sep 22 | Dec 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 2 | 2 | 2 | 3 | 2 | 16 | 8 | 13 | 7 | 6 |
| Net Income | - | - | - | - | - | - | - | - | - | $-119.12M | $-103.16M | $-76.21M | $-69.05M | $-27.96M |
| Avg Forecast | $-62.10M | $-75.76M | $-87.99M | $-99.10M | $-77.44M | $-119.84M | $-114.23M | $-107.70M | $-100.13M | $-103.01M | $-104.49M | $-84.63M | $-80.84M | $-36.66M |
| High Forecast | $-62.10M | $-75.76M | $-87.99M | $-99.10M | $-77.44M | $-119.84M | $-114.23M | $-89.75M | $-80.41M | $-75.19M | $-104.49M | $-84.63M | $-80.84M | $-29.32M |
| Low Forecast | $-62.10M | $-75.76M | $-87.99M | $-99.10M | $-77.44M | $-119.84M | $-114.23M | $-114.88M | $-127.06M | $-125.20M | $-104.49M | $-84.63M | $-80.84M | $-43.99M |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.16% | 0.99% | 0.90% | 0.85% | 0.76% |
Karuna Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. KRTX's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Karuna Therapeutics SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Dec 22 | Sep 22 | Dec 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 2 | 2 | 2 | 3 | 2 | 16 | 8 | 13 | 7 | 6 |
| SG&A | - | - | - | - | - | - | - | - | - | $32.27M | $27.42M | $24.31M | $19.13M | $20.06M |
| Avg Forecast | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Karuna Therapeutics's average Quarter SG&A projection for Dec 23 is -, based on 2 Wall Street analysts, with a range of - to -. The forecast indicates a -100.00% fall compared to KRTX last annual SG&A of $32.27M (Sep 23).
Karuna Therapeutics EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Dec 22 | Sep 22 | Dec 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 2 | 2 | 2 | 3 | 2 | 16 | 8 | 13 | 7 | 6 |
| EPS | - | - | - | - | - | - | - | - | - | $-3.16 | $-2.75 | $-2.22 | $-2.13 | $-0.94 |
| Avg Forecast | $-1.64 | $-2.01 | $-2.33 | $-2.62 | $-2.05 | $-3.17 | $-3.02 | $-2.85 | $-2.65 | $-2.73 | $-2.77 | $-2.24 | $-2.14 | $-1.73 |
| High Forecast | $-1.64 | $-2.01 | $-2.33 | $-2.62 | $-2.05 | $-3.17 | $-3.02 | $-2.38 | $-2.13 | $-1.99 | $-2.77 | $-2.24 | $-2.14 | $-1.73 |
| Low Forecast | $-1.64 | $-2.01 | $-2.33 | $-2.62 | $-2.05 | $-3.17 | $-3.02 | $-3.04 | $-3.36 | $-3.31 | $-2.77 | $-2.24 | $-2.14 | $-1.73 |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.16% | 0.99% | 0.99% | 1.00% | 0.54% |
According to undefined Wall Street analysts, Karuna Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to KRTX previous annual EPS of $NaN (undefined).
Karuna Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| XFOR | X4 Pharmaceuticals | $0.71 | $3.67 | 416.90% | Buy |
| DAWN | Day One Biopharmaceuticals | $14.13 | $38.80 | 174.59% | Buy |
| ABOS | Acumen Pharmaceuticals | $2.60 | $7.00 | 169.23% | Buy |
| EWTX | Edgewise Therapeutics | $18.83 | $48.00 | 154.91% | Buy |
| INZY | Inozyme Pharma | $6.00 | $14.67 | 144.50% | Buy |
| APLS | Apellis Pharmaceuticals | $37.62 | $75.81 | 101.52% | Buy |
| MREO | Mereo BioPharma Group | $4.28 | $6.75 | 57.71% | Buy |
| CYTK | Cytokinetics | $55.88 | $80.92 | 44.81% | Buy |
| TERN | Terns Pharmaceuticals | $8.96 | $12.50 | 39.51% | Buy |
| DYN | Dyne Therapeutics | $34.06 | $43.88 | 28.83% | Buy |
| AMLX | Amylyx Pharmaceuticals | $2.62 | $3.33 | 27.10% | Buy |
| DICE | DICE Therapeutics | $47.55 | $60.00 | 26.18% | Buy |
| BPMC | Blueprint Medicines | $88.90 | $101.50 | 14.17% | Buy |
| KRTX | Karuna Therapeutics | $329.83 | $257.50 | -21.93% | Buy |
KRTX Forecast FAQ
Is Karuna Therapeutics a good buy?
Yes, according to 6 Wall Street analysts, Karuna Therapeutics (KRTX) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 5 'Buy' recommendations, accounting for 83.33% of KRTX's total ratings.
What is KRTX's price target?
Karuna Therapeutics (KRTX) average price target is $257.5 with a range of $150 to $330, implying a -21.93% from its last price of $329.83. The data is based on 6 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Karuna Therapeutics stock go up soon?
According to Wall Street analysts' prediction for KRTX stock, the company can go down by -21.93% (from the last price of $329.83 to the average price target of $257.5), up by 0.05% based on the highest stock price target, and down by -54.52% based on the lowest stock price target.
Can Karuna Therapeutics stock reach $500?
KRTX's average twelve months analyst stock price target of $257.5 does not support the claim that Karuna Therapeutics can reach $500 in the near future.
What are Karuna Therapeutics's analysts' financial forecasts?
Karuna Therapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $59.94M (high $59.94M, low $59.94M), average EBITDA is $-11.988M (high $-11.988M, low $-11.988M), average net income is $-419M (high $-401M, low $-426M), average SG&A $0 (high $0, low $0), and average EPS is $-11.096 (high $-10.621, low $-11.286). KRTX's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $154.2M (high $154.2M, low $154.2M), average EBITDA is $-30.841M (high $-30.841M, low $-30.841M), average net income is $-325M (high $-325M, low $-325M), average SG&A $0 (high $0, low $0), and average EPS is $-8.601 (high $-8.601, low $-8.601).
Did the KRTX's actual financial results beat the analysts' financial forecasts?
Based on Karuna Therapeutics's last annual report (Dec 2022), the company's revenue was $10.64M, beating the average analysts forecast of $923.81K by 1051.43%. Apple's EBITDA was $-290M, beating the average prediction of $-185K by 156684.17%. The company's net income was $-276M, beating the average estimation of $-165M by 66.99%. Apple's SG&A was $76.07M, beating the average forecast of $0 by 0%. Lastly, the company's EPS was $-8.74, beating the average prediction of $-4.38 by 99.55%. In terms of the last quarterly report (Dec 2022), Karuna Therapeutics's revenue was $5.28M, beating the average analysts' forecast of $7.14K by 73790.52%. The company's EBITDA was $-85.036M, beating the average prediction of $-1.428K by 5954801.96%. Karuna Therapeutics's net income was $-76.212M, missing the average estimation of $-84.632M by -9.95%. The company's SG&A was $24.31M, beating the average forecast of $0 by 0%. Lastly, the company's EPS was $-2.22, missing the average prediction of $-2.24 by -0.90%